Form 4 for TNYA Tenaya Therapeutics, Inc.

Accepted 2024-08-16 00:00:00 ET · period of report 2024-08-16 · accession 0000950170-24-098234 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2024-08-16	2024-08-16	TNYA	Ali Faraz	CEO, Dir	S - Sale	$2.89	-9,748	188.3K	-5%	-$28.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-08-16	S	D	5,802	$2.89	192,277	D	—	—	(F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F3) Includes 152,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
2	Common	Common Stock	2024-08-16	S	D	3,946	$2.89	188,331	D	—	—	(F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F3) Includes 152,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.